– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation –
SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ --...

Related Keywords

California , United States , Northwestern University , Illinois , Rochester , New York , Portland , Oregon , Alabama , Germany , Canada , Sugarloaf , San Francisco , Bonn , Nordrhein Westfalen , Washington , Chicago , Berlin , Thomas Bieber , Jonathan Zalevsky , David Rosmarin , Andrew Blauvelt , Mary Tagliaferri , Zachary Lee , Brian Kotzin , Eli Lilly , Vivian Wu , Sohail Chaudhry , Sstephen Schleicher , Danni Yu , Mario Marcondes , Raj Chovatiya , David Rosen , Alisa Beck , Timothy Rodgers , Jonathan Silverberg , Yi Liu , Carsten Schmitz , Melinda Gooderham , Christie Fanton , Ajay Nirula , Nektar Therapeutics , Research Development , Exchange Commission On , Indiana University School Of Medicine , Oregon Medical Research Center , Icans School Of Medicine At Mt , European Academy Of Dermatology , Queen University , Skin Sciences , Department Of Medicine , Rochester Medical Center , Dermdox Centers For Dermatology , Feinberg School , George Washington University School , Allergy Research And Education , Efficacy Data , Severe Atopic Dermatitis , Late Breaking Oral Presentation , Senior Vice President , Chief Research , Development Officer , Single Agent Rezpegaldesleukin , Selective Regulatoryt Cell Inducing , Atopic Dermatitis , Final Results , Randomized Phase , Late Breaking , George Washington University School Of Medicine , University School , School Of Medicine , Dox Centers , Placebo Controlled Study , Moderate To Severe Atopic Dermatitis , Medical Research Center , Center For Allergy Research And Education , University Of Bonn , Annual Report , Exchange Commission , Markets ,